Trimbow

Therapeutic Indication:

Trimbow is indicated for maintenance treatment in adult patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD), who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

• Composition: Beclometasone Dipropionate 87.4 mcg/Actuation, Formoterol Fumarate Dihydrate 5.2 mcg/Actuation, Glycopyrronium as Bromide 9 mcg/Actuation.
• Pharmaceutical Form: Pressurized Solution for inhalation.
• Method of Administration: Inhalation.
• How Supplied: Single Inhaler, 120 Actuations.
• Manufacturer: Chiesi Farmaceutici, Italy.